Diabetes
Refine Search
Biosimilars
Samsung Bioepis releases its first US biosimilar Market Report 18 April 2023
Pharmaceutical
French drugmaker Sanofi has signed a three-year Memorandum of Understanding (MoU) with the Ministry of Health of Ghana. 17 April 2023
Pharmaceutical
As interest in GLP-1 agonists soars, AstraZeneca (LSE: AZN) has changed tack, stopping work on a daily injectable option in order to focus on an alternative wit 17 April 2023
Biotechnology
Novo Nordisk inks deal on cell therapies for diabetes and obesity 12 April 2023
Pharmaceutical
India denies Boehringer Ingelheim's interim injunction on linagliptin patent 12 April 2023
Pharmaceutical
Novo Nordisk to stop supplies of diabetes drug Ozempic to Russia this year 29 March 2023
Pharmaceutical
Bayer’s Kerendia backed for NHS use in England 24 March 2023
Pharmaceutical
Biomolecular condensate specialist Dewpoint Therapeutics has secured a significant research and development deal with Denmark’s Novo Nordisk. 23 March 2023
Biotechnology
The week in pharma: action, reaction and insight – week to March 17, 2023 19 March 2023
Pharmaceutical
Sanofi joins pack to reduce insulin costs, cutting US Lantus list price by 78% 17 March 2023
Pharmaceutical
In a highly unusual move, the UK pharmaceutical industry’s trade body has suspended the membership of Danish diabetes giant Novo Nordisk (NOV: N). 16 March 2023
Pharmaceutical
The impact of US President Joe Biden's Inflation Reduction Act is beginning to be felt, as Danish diabetes giant Novo Nordisk (NOV: N) announced plans to slash 15 March 2023
Biotechnology
Provention Bio soars on news of takeover bid 13 March 2023
Biotechnology
MacroGenics sells royalty interest in Tzield for up to $200 million 9 March 2023
Pharmaceutical
Markets were not hugely worried by predictions for a tough 2023 for Merck KGaA, with the German company’s share price only marginally down late Thursday. 2 March 2023
Pharmaceutical
Lilly says it will cut insulin prices by 70% 2 March 2023
Biotechnology
Enthera names former Roche exec as CMO 16 February 2023
Generics
Tentative FDA approval for two Zydus generics 15 February 2023
Pharmaceutical
With analysts forecasting revenues to exceed $11 billion, British pharma major AstraZeneca delivered as expected in the final quarter, taking in $11.3 billion, 9 February 2023
Pharmaceutical
NICE draft guidance does not recommend Jardiance in new HF indication 8 February 2023
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze